Hormone-Refractory Prostate Cancer Completed Phase 2 Trials for Eribulin (DB08871)

Also known as: Hormone-refractory Prostate Cancer / Hormone refractory prostate cancer

IndicationStatusPhase
DBCOND0030169 (Hormone-Refractory Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00337077Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyTreatment